Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of “Moderate Buy” by Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has earned an average recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $117.8182.

A number of research analysts have weighed in on DNTH shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Raymond James Financial restated a “strong-buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Wedbush increased their price objective on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th.

Insider Buying and Selling at Dianthus Therapeutics

In other news, SVP Adam M. Veness sold 30,000 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the completion of the transaction, the senior vice president owned 30,000 shares in the company, valued at approximately $2,424,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the completion of the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $362,480. This trade represents a 86.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 87,779 shares of company stock worth $7,985,235 over the last ninety days. 3.02% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Dianthus Therapeutics by 24.7% in the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after purchasing an additional 406,254 shares in the last quarter. UBS Group AG lifted its stake in shares of Dianthus Therapeutics by 342.6% during the 4th quarter. UBS Group AG now owns 606,620 shares of the company’s stock valued at $24,999,000 after buying an additional 469,547 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at approximately $765,000. BNP Paribas Financial Markets boosted its holdings in Dianthus Therapeutics by 1,275.3% in the 4th quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock worth $19,606,000 after buying an additional 441,156 shares during the period. Finally, SummitTX Capital L.P. boosted its holdings in Dianthus Therapeutics by 13.8% in the 1st quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock worth $8,396,000 after buying an additional 12,118 shares during the period. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH opened at $106.92 on Friday. The company has a market capitalization of $5.85 billion, a P/E ratio of -25.89 and a beta of 1.20. The company’s 50-day moving average is $92.63 and its 200 day moving average is $78.34. Dianthus Therapeutics has a fifty-two week low of $18.08 and a fifty-two week high of $114.55.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. As a group, research analysts predict that Dianthus Therapeutics will post -3.82 earnings per share for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.